Apelin Is a Crucial Factor for Hypoxia-Induced Retinal Angiogenesis
- 1 November 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 30 (11) , 2182-2187
Abstract
Objective— To investigate the role of endogenous apelin in pathological retinal angiogenesis. Methods and Results— The progression of ischemic retinal diseases, such as diabetic retinopathy, is closely associated with pathological retinal angiogenesis, mainly induced by vascular endothelial growth factor (VEGF) and erythropoietin. Although antiangiogenic therapies using anti-VEGF drugs are effective in treating retinal neovascularization, they show a transient efficacy and cause general adverse effects. New therapeutic target molecules are needed to resolve these issues. It was recently demonstrated that the apelin/APJ system, a newly deorphanized G protein–coupled receptor system, is involved in physiological retinal vascularization. Retinal angiography and mRNA expression were examined during hypoxia-induced retinal angiogenesis in a mouse model of oxygen-induced retinopathy. Compared with age-matched control mice, retinal apelin expression was dramatically increased during the hypoxic phase in oxygen-induced retinopathy model mice. APJ was colocalized in proliferative cells, which were probably endothelial cells of the ectopic vessels in the vitreous body. Apelin deficiency hardly induced hypoxia-induced retinal angiogenesis despite the upregulation of VEGF and erythropoietin mRNA in oxygen-induced retinopathy model mice. Apelin small and interfering RNA suppressed the proliferation of endothelial cells independent of the VEGF/VEGF receptor 2 signaling pathway. Conclusion— These results suggest that apelin is a prerequisite factor for hypoxia-induced retinal angiogenesis.Keywords
This publication has 30 references indexed in Scilit:
- Suppression of Retinal Neovascularization by Erythropoietin siRNA in a Mouse Model of Proliferative RetinopathyInvestigative Ophthalmology & Visual Science, 2009
- Vascular endothelial growth factor and diabetic complicationsProgress in Retinal and Eye Research, 2008
- Apelin/APJ signaling system: a potential link between adipose tissue and endothelial angiogenic processesThe FASEB Journal, 2008
- The Role of Apelin in Cardiovascular Function and Heart FailureEuropean Journal of Heart Failure, 2008
- Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategyDiabetologia, 2008
- Spatial and temporal role of the apelin/APJ system in the caliber size regulation of blood vessels during angiogenesisThe EMBO Journal, 2008
- Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: Implications for structural differences in macular profilesExperimental Eye Research, 2006
- Erythropoietin as a Retinal Angiogenic Factor in Proliferative Diabetic RetinopathyNew England Journal of Medicine, 2005
- Isolation and Characterization of a Novel Endogenous Peptide Ligand for the Human APJ ReceptorBiochemical and Biophysical Research Communications, 1998
- Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.Proceedings of the National Academy of Sciences, 1995